Is Tirzepatide Like Ozempic? A Clear, Evidence-Led Comparison

Step 1: Understand what each medicine actually is

Tirzepatide is the active ingredient in Mounjaro, made by Eli Lilly. It is a dual GIP and GLP-1 receptor agonist, the only weight-loss medicine licensed in the UK that activates both receptors simultaneously. GIP and GLP-1 are gut hormones involved in appetite regulation, blood-sugar control and gastric emptying. Activating both pathways at once is what makes tirzepatide structurally different from any semaglutide product.

Ozempic contains semaglutide, made by Novo Nordisk, and is a GLP-1 receptor agonist only. It targets a single receptor pathway. In the UK, Ozempic holds a licence for type 2 diabetes management, not for weight loss. This is a firm regulatory line, not a technicality. The MHRA is clear that GLP-1 medicines should not be used for cosmetic or quick weight loss, and the NHS medicines page for tirzepatide outlines its approved indication separately from diabetes products.

So the first practical step when someone asks whether Ozempic is a tirzepatide is to separate the brand name from the purpose. They share a broad pharmacological family. Their licensed uses in the UK differ significantly.

Step 2: Compare their licensed indications, UK availability and evidence

The table below sets out the key differences using verified UK facts.

A note on the evidence column: the weight-loss trial programme for tirzepatide (SURMOUNT) involved thousands of adults with obesity. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 participants and reported around 20–21% average body-weight reduction at the highest dose over 72 weeks. Comparing that directly to Ozempic data would be misleading because Ozempic trials were designed around diabetes outcomes, not body weight. The fair weight-loss comparison is tirzepatide versus Wegovy, explored in detail in our Wegovy vs Mounjaro comparison.

Step 3: Understand what is actually licensed for weight loss in the UK

If your interest is weight management rather than diabetes treatment, the two medicines with a UK weight-loss licence are:

Mounjaro (tirzepatide), recommended by NICE under TA1026 for adults with a BMI of at least 35 and one or more weight-related conditions within NHS specialist services, with lower thresholds for some ethnic backgrounds. Privately, the licensed eligibility starts at BMI ≥30, or ≥27 with a qualifying condition, a prescriber makes the final assessment.

Wegovy (semaglutide 2.4mg), a different product from Ozempic, carrying its own weight-management licence. People sometimes assume Ozempic and Wegovy are the same thing because both contain semaglutide, and our page on whether Ozempic and tirzepatide are the same explains exactly where those similarities end and where the differences begin. Our page on how Wegovy compares to Mounjaro covers that in full.

There is one misconception worth gently setting aside: Ozempic is not a loophole route to Mounjaro or Wegovy. Prescribing it for weight loss in the UK would be off-label, and no reputable prescriber uses it that way when licensed alternatives exist. The confusion often comes from early media coverage, before Wegovy and Mounjaro became widely available privately.

Which suits you, and how a prescriber works that out

Even once you know the licence landscape, choosing between Mounjaro and Wegovy for weight management is a clinical decision, not a product preference. A prescriber considers your medical history, any current medicines, previous treatment, comorbidities and personal circumstances. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity, but greater average results across a trial population do not mean the same result applies to every individual.

Our prescribers review every consultation personally on the day it arrives. You can read more about how the clinical team works on our clinical team page, and explore both licensed weight-loss treatments on our weight-loss overview. If you are still unsure how these medicines are classified, our page explaining whether Ozempic is tirzepatide or semaglutide clarifies the terminology in plain language, and if you want to read specifically about whether these two molecules are the same thing, our page on whether tirzepatide is the same as Ozempic goes into the chemistry. Which medicine suits you is a clinical decision our prescribers make with you, not one this page can make on their behalf.